Gencor Pacific is embarking on a human trial in Australia to validate the immunity-boosting ability of Palmitoylethanolamide (PEA) against the backdrop of the rising demand for immunity supplements amid the worldwide spread of COVID-19.
The trial, set to begin in the latter half of 2020, will ‘investigate the impact of PEA on the symptomatic relief of flu symptoms and its ability to boost the immune system’, states the NutriIngredients-Asia article.
It will add to existing Gencor research into PEA, including studies exploring its efficacy as a treatment for inflammation, muscle recovery, joint pain and insomnia.
Read the full article by Tingmin Koe, published on 19 March 2020.
Source: Immunity innovation: Gencor to study PEA’s immune boosting effects via human trial I FoodNavigator Asia